Laboratorios Farmaceuticos RoviLABFF 93 Forward Rate of Return (Yacktman) % is 17.01% as of Mar. 2026, which is 7% below its 10-year median of 18.29. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 635 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 77.64% on this metric.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Laboratorios Farmaceuticos Rovi's forward rate of return for was 17.01%.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Forward Rate of Return (Yacktman) % or its related term are showing as below:
LABFF'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.28 Med: 18.29 Max: 23.39
Current: 18.09
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest Forward Rate of Return was 23.39. The lowest was -5.28. And the median was 18.29.
LABFF's Forward Rate of Return (Yacktman) % is ranked better than 77.64% of 635
companies
in the Drug Manufacturers industry
Industry Median: 6.44
vs LABFF: 18.09
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
Laboratorios Farmaceuticos Rovi Forward Rate of Return (Yacktman) % Related Terms
Laboratorios Farmaceuticos Rovi Forward Rate of Return (Yacktman) % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi Forward Rate of Return (Yacktman) % Chart
LABFF vs ZTS, UTHR, VTRS: Forward Rate of Return (Yacktman) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Forward Rate of Return (Yacktman) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Forward Rate of Return (Yacktman) % falls into.
Laboratorios Farmaceuticos Rovi Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of 17.01% mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Forward Rate of Return (Yacktman) % of 17.01% as of Mar. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is near median its historical median of 18.29. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #142 out of 635 companies in the Drug Manufacturers industry, placing it in the top 22.4%.
Is Laboratorios Farmaceuticos Rovi's Forward Rate of Return (Yacktman) % too high?
Laboratorios Farmaceuticos Rovi's current Forward Rate of Return (Yacktman) % of 17.01% is near median its 10-year median of 18.29. The Drug Manufacturers industry median Forward Rate of Return (Yacktman) % is 6.44. Laboratorios Farmaceuticos Rovi's value of 17.01% is 164.1% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #142 out of 635 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Forward Rate of Return (Yacktman) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #142 out of 635 companies for Forward Rate of Return (Yacktman) %. This places Laboratorios Farmaceuticos Rovi in the top 22% of its industry — outperforming the majority of peers. The industry median Forward Rate of Return (Yacktman) % is 6.44. Laboratorios Farmaceuticos Rovi's value of 17.01% is 164.1% above this benchmark. While the company's 10-year median is 18.29 vs. the industry median of 6.44, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Drug Manufacturers company?
The median Forward Rate of Return (Yacktman) % among Drug Manufacturers companies is 6.44, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Forward Rate of Return (Yacktman) % of 17.01% is 164.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Forward Rate of Return (Yacktman) % is 6.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Forward Rate of Return (Yacktman) % is 17.01%, which is near median its own 10-year median of 18.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Forward Rate of Return (Yacktman) % of 17.01%. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Forward Rate of Return (Yacktman) % is 17.01%, which is near median its 10-year median of 18.29 and 164.1% above the Drug Manufacturers industry median of 6.44. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Forward Rate of Return (Yacktman) % is 17.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
Forward Rate of Return (Yacktman) %: 17.01% (near median its 10-year median of 18.29)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
Industry Position: 164.1% above the Drug Manufacturers median (#142 of 635)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
